Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.96
LGND's Cash to Debt is ranked higher than
56% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. LGND: 0.96 )
LGND' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.96

Equity to Asset 0.16
LGND's Equity to Asset is ranked higher than
53% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LGND: 0.16 )
LGND' s 10-Year Equity to Asset Range
Min: -0.83   Max: 0.68
Current: 0.16

-0.83
0.68
F-Score: 6
Z-Score: 0.40
M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 29.17
LGND's Operating margin (%) is ranked higher than
95% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. LGND: 29.17 )
LGND' s 10-Year Operating margin (%) Range
Min: -1963.29   Max: 30.51
Current: 29.17

-1963.29
30.51
Net-margin (%) 12.15
LGND's Net-margin (%) is ranked higher than
89% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. LGND: 12.15 )
LGND' s 10-Year Net-margin (%) Range
Min: -798.16   Max: 2184.64
Current: 12.15

-798.16
2184.64
ROE (%) 12.76
LGND's ROE (%) is ranked higher than
93% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. LGND: 12.76 )
LGND' s 10-Year ROE (%) Range
Min: -1046.55   Max: 997.71
Current: 12.76

-1046.55
997.71
ROA (%) 5.00
LGND's ROA (%) is ranked higher than
90% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. LGND: 5.00 )
LGND' s 10-Year ROA (%) Range
Min: -95.66   Max: 112.83
Current: 5

-95.66
112.83
ROC (Joel Greenblatt) (%) 2304.83
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. LGND: 2304.83 )
LGND' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1430.01   Max: 1805.8
Current: 2304.83

-1430.01
1805.8
Revenue Growth (3Y)(%) 25.30
LGND's Revenue Growth (3Y)(%) is ranked higher than
92% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. LGND: 25.30 )
LGND' s 10-Year Revenue Growth (3Y)(%) Range
Min: -64.8   Max: 90.1
Current: 25.3

-64.8
90.1
» LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

LGND Guru Trades in Q4 2013

Joel Greenblatt 13,803 sh (+124.95%)
RS Investment Management 1,315,098 sh (+122.38%)
Paul Tudor Jones Sold Out
» More
Q1 2014

LGND Guru Trades in Q1 2014

Steven Cohen 4,601 sh (New)
Paul Tudor Jones 4,252 sh (New)
Joel Greenblatt Sold Out
RS Investment Management 1,222,507 sh (-7.04%)
» More
Q2 2014

LGND Guru Trades in Q2 2014

Ken Fisher 36,908 sh (New)
Jim Simons 38,594 sh (New)
Joel Greenblatt 55,492 sh (New)
RS Investment Management 1,392,185 sh (+13.88%)
Paul Tudor Jones Sold Out
» More
Q3 2014

LGND Guru Trades in Q3 2014

Paul Tudor Jones 5,200 sh (New)
Joel Greenblatt 552,053 sh (+894.83%)
RS Investment Management 1,493,635 sh (+7.29%)
Jim Simons Sold Out
Ken Fisher 35,258 sh (-4.47%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 894.83%0.23%$46.99 - $64.52 $ 52.32-1%552053
Joel Greenblatt 2014-06-30 New Buy0.04%$59.74 - $70.19 $ 52.32-20%55492
Ken Fisher 2014-06-30 New Buy$59.74 - $70.19 $ 52.32-20%36908
Joel Greenblatt 2014-03-31 Sold Out 0.02%$51.52 - $79.58 $ 52.32-21%0
Joel Greenblatt 2013-12-31 Add 124.95%0.01%$44.86 - $57.95 $ 52.320%13803
Joel Greenblatt 2013-09-30 New Buy0.01%$38.69 - $49.66 $ 52.3216%6136
Daniel Loeb 2011-12-31 Sold Out 0.46%$10.59 - $15.73 $ 52.32310%0
George Soros 2011-09-30 Sold Out 0.0017%$10.89 - $15.95 $ 52.32297%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 169.90
LGND's P/E(ttm) is ranked higher than
88% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LGND: 169.90 )
LGND' s 10-Year P/E(ttm) Range
Min: 0.99   Max: 269.4
Current: 169.9

0.99
269.4
P/B 24.40
LGND's P/B is ranked higher than
60% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. LGND: 24.40 )
LGND' s 10-Year P/B Range
Min: 11.11   Max: 182
Current: 24.4

11.11
182
P/S 20.50
LGND's P/S is ranked higher than
76% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. LGND: 20.50 )
LGND' s 10-Year P/S Range
Min: 3.13   Max: 754
Current: 20.5

3.13
754
PFCF 79.40
LGND's PFCF is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LGND: 79.40 )
LGND' s 10-Year PFCF Range
Min: 33.11   Max: 425.29
Current: 79.4

33.11
425.29
EV-to-EBIT 63.99
LGND's EV-to-EBIT is ranked higher than
90% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LGND: 63.99 )
LGND' s 10-Year EV-to-EBIT Range
Min: -6946.9   Max: 2376.7
Current: 63.99

-6946.9
2376.7
Current Ratio 10.77
LGND's Current Ratio is ranked higher than
88% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. LGND: 10.77 )
LGND' s 10-Year Current Ratio Range
Min: 0.28   Max: 10.77
Current: 10.77

0.28
10.77
Quick Ratio 10.71
LGND's Quick Ratio is ranked higher than
88% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. LGND: 10.71 )
LGND' s 10-Year Quick Ratio Range
Min: 0.26   Max: 10.71
Current: 10.71

0.26
10.71

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.70
LGND's Price/Median PS Value is ranked higher than
77% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. LGND: 1.70 )
LGND' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 56.52
Current: 1.7

0.31
56.52
Earnings Yield (Greenblatt) 1.60
LGND's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. LGND: 1.60 )
LGND' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.9
Current: 1.6

0.1
1.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 

More From Other Websites
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
11:30 am Ligand Pharma confirmed that its partner Pfizer (PFE) has... Dec 21 2014
LIGAND PHARMACEUTICALS INC Financials Dec 19 2014
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated... Dec 19 2014
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated... Dec 19 2014
10-K/A for Ligand Pharmaceuticals, Inc. Dec 14 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report Dec 12 2014
10-K/A for Ligand Pharmaceuticals, Inc. Dec 03 2014
Coverage initiated on Ligand Pharma by Deutsche Bank Dec 02 2014
UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On... Dec 02 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report Dec 01 2014
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak... Nov 18 2014
Ligand Provides Highlights from Today’s Analyst Day Event Nov 18 2014
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Nov 18 2014
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug Nov 13 2014
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
10-Q for Ligand Pharmaceuticals, Inc. Nov 03 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Oct 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK